J Cancer 2019; 10(24):6088-6094. doi:10.7150/jca.33244

Research Paper

High expression of DOCK2 indicates good prognosis in acute myeloid leukemia

Ning Hu1, Yifan Pang2, Hongmian Zhao1, Chaozeng Si3, Hui Ding1, Li Chen1, Chao Wang1, Tong Qin1, Qianyu Li1, Yu Han1, Yifeng Dai4, Yijie Zhang5, Jinlong Shi6, Depei Wu7, Xinyou Zhang8✉, Zhiheng Cheng4✉, Lin Fu1,9,10✉

1. Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China
2. Department of Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA
3. Department of Operations and Information Management, China-Japan Friendship Hospital, Beijing, 100029, China
4. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
5. Department of Respiratory, Huaihe Hospital of Henan University, Kaifeng, 475000, China
6. Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China
7. Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
8. Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, China
9. Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China
10. Translational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Hu N, Pang Y, Zhao H, Si C, Ding H, Chen L, Wang C, Qin T, Li Q, Han Y, Dai Y, Zhang Y, Shi J, Wu D, Zhang X, Cheng Z, Fu L. High expression of DOCK2 indicates good prognosis in acute myeloid leukemia. J Cancer 2019; 10(24):6088-6094. doi:10.7150/jca.33244. Available from http://www.jcancer.org/v10p6088.htm

File import instruction

Abstract

DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML). We first analyzed data of 85 AML patients who were treated with chemotherapy and had available DOCK1 to DOCK11 expression information and found that DOCK1 and DOCK2 had prognostic significance in AML. In view of the known prognosis of DOCK1 in AML, we then explored the prognostic role of DOCK2. One hundred fifty-six AML patients with DOCK2 expression data were extracted from The Cancer Genome Atlas (TCGA) database and enrolled in this study. Patients were divided based on treatment modality into the chemotherapy group and the allogeneic hematopoietic stem cell transplant (allo-HSCT) group. Each group was divided into two groups by the median expression levels of DOCK2. In the chemotherapy group, high DOCK2 expression was associated with longer event-free survival (EFS, P=0.001) and overall survival (OS, P=0.007). In the allo-HSCT group, EFS and OS were not significantly different between high and low DOCK2 expression groups. Multivariate analysis showed that high DOCK2 expression was an independent favorable prognostic factor for both EFS and OS in all patients (all P<0.05). In conclusion, our results indicated that high DOCK2 expression, in contrast to DOCK1, conferred good prognosis in AML.

Keywords: acute myeloid leukemia, DOCK2, allogeneic hematopoietic stem cell transplantation, chemotherapy, prognosis